scPharmaceuticals Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- scPharmaceuticals Inc., a biopharmaceutical company focused on developing and commercializing subcutaneous therapies for cardiorenal conditions, offers FUROSCIX (furosemide injection), an FDA-approved proprietary formulation delivered via the on-body sc2Wear Infusor for at-home treatment of edema associated with heart failure and chronic kidney disease including nephrotic syndrome; the company also advances the SCP-111 program, a furosemide 80mg/1mL autoinjector designed to reduce administration time from five hours to under ten seconds, with a supplemental New Drug Application targeted for submission in the third quarter of 2025. Founded in 2013 and headquartered in Burlington, Massachusetts, scPharmaceuticals operates primarily in the United States, targeting patients with heart failure, chronic kidney disease, and related fluid overload conditions through its drug-device combination platform aimed at reducing healthcare costs and enabling outpatient self-administration of intravenous-strength therapies. In October 2025, scPharmaceuticals was acquired by MannKind Corporation in a $296.5 million all-stock transaction, integrating its cardiorenal portfolio including FUROSCIX into MannKind's cardiometabolic and orphan lung disease focus to accelerate revenue growth and expand market reach; earlier in 2025, the FDA approved expansion of the FUROSCIX indication to chronic kidney disease with commercial launch in April, following strong 96% year-over-year net sales growth to $27.8 million for the first half of the year, and in August 2024 the company secured up to $125 million in non-dilutive debt and royalty financings from Perceptive Advisors to support commercialization.
SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTLE and SCPH on Behalf of Shareholders
SCPH Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of scPharmaceuticals to MannKind
SCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of scPharmaceuticals Inc. Is Fair to Shareholders
Shareholder Alert: The Ademi Firm Investigates Whether scPharmaceuticals Inc. Is Obtaining a Fair Price for Its Public Shareholders
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111
scPharmaceuticals Inc. (SCPH) Q2 2025 Earnings Call Transcript
scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates
scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update
scPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025
scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?
scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025
scPharmaceuticals Inc. (SCPH) Q1 2025 Earnings Call Transcript
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates
scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025
scPharmaceuticals Announces Participation in Three Upcoming Investor Conferences
scPharmaceuticals Inc. (SCPH) Q4 2024 Earnings Call Transcript
ScPharmaceuticals, Inc. (SCPH) Reports Q4 Loss, Tops Revenue Estimates